 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
SGI-RUB-048
NCT00113256
|
|
| |
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
|
|
|
|
Phase III
|
|
|
|
EFC6596
XRP9881, NCT00417209
|
|
| |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
|
|
|
Phase III
|
|
|
|
A6181114
NCT00428220
|
|
| |
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
|
|
|
Phase III
|
|
|
|
A4061028
NCT00471146
|
|
| |
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
|
|
|
|
Phase III
|
|
|
|
EFC10547
AVE0005, EudraCT 2007-003476-19, NCT00574275
|
|
| |
S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
|
|
|
|
Phase III
|
|
|
|
EFC10203
S-1 - FI, NCT00602745
|
|
| |
Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
PANC0002
95533, CPTK787AUS08, NCT00185588, PANC0002, NCT00185588
|
|
| |
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
VU-VICC-GI-0622
VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
| |
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
|
|
|
|
Phase II, Phase I
|
|
|
|
22706
NCT00390182
|
|
| |
Gemcitabine (GEMZAR) Plus ABI-007 (ABRAXANE)In Patients With Advanced Metastatic Pancreatic Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
CA040
NCT00398086
|
|
